Introduction
The evolution of vertebrate species of far greater mass and somatic complexity than invertebrates involved the appearance of specialized circulatory systems to insure that every cell received adequate O 2 . The most significant innovation within the circulatory system was the erythrocyte, a cell specialized for the transport of gases (O 2 , CO 2 , and NO) in and out of the organism. This review will focus on the molecular mechanisms that regulate red blood cell production as a function of tissue oxygenation and hereditable disorders of oxygen homeostasis that result in excess erythropoiesis.
Molecular Mechanism of Oxygen Sensing
In mammals, O 2 sensing occurs at many levels, leading to both acute and chronic adaptation. The carotid body, which is located at the bifurcation of the internal and external carotid arteries, contains highly specialized chemosensory cells. These glomus cells depolarize in response to reduction in arterial blood PO 2 (hypoxemia), resulting in stimulation of the brain stem centers that control the respiratory and cardiovascular systems, which leads to rapid changes in ventilation, heart rate, and blood pressure that serve to increase O 2 uptake in the lungs and O 2 delivery to the tissues. 1 The second major systemic O 2 sensing system is located in the inner cortex and outer medulla of the kidney, where specialized interstitial cells respond to decreased tissue PO 2 (hypoxia), resulting e.g. from hemorrhage or anemia, by producing and secreting into the circulation erythropoietin (EPO), a glycoprotein hormone that binds to erythroid progenitors in bone marrow and stimulates their For personal use only. on October 3, 2017. by guest www.bloodjournal.org From survival, proliferation, and differentiation. 2 In contrast to the rapidity of the responses mediated by the carotid body, the increase in blood O 2 -carrying capacity that is mediated by EPO occurs on the order of days rather than seconds, reflecting the developmental program of erythropoiesis.
Analysis of the human 3,4 and mouse 5 genes encoding EPO revealed the presence of a cis-acting hypoxia response element (HRE), which was located in the 3'-flanking region. Under hypoxic conditions, the HRE was occupied by a DNA binding protein, which was designated hypoxia-inducible factor 1 (HIF-1). 6 The purification of HIF-1 by DNA affinity chromatography revealed that it is a heterodimeric protein consisting of HIF-1α and HIF-1β subunits 7 and cDNA isolation revealed that both subunits were members of a subfamily of basic helixloop-helix transcription factors that contain a PAS domain, which is an accessory dimerization domain that was originally identified the Per, Arnt, and Sim proteins.
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Analysis of knockout mice revealed that expression of HIF-1α and HIF-1β are required for normal development of the heart, blood vessels, and blood cells, i.e. all three components of the circulatory system are dependent upon HIF-1. 9-12 In addition to its broad effects on development, HIF-1 mediates a multitude of cellular and systemic physiological and pathophysiological responses to hypoxia/ischemia in postnatal life. The proline (PHD2) and asparagine (FIH-1) hydroxylases both use O 2 and α-ketoglutarate (also known as 2-oxoglutarate) as substrates and generate CO 2 and succinate as by-products. 27 The catalytic center of these dioxygenases contains nonheme Fe (II), which is oxidized to Fe (III) during the hydroxylation reaction, with ascorbate required for regeneration of Fe (II). As a result, the activity of the hydroxylases may be affected by changes in the concentration of O 2 , iron and divalent metal ions, ascorbate, reactive oxygen species, nitric oxide, and tricarboxylic acid cycle intermediates, 28 suggesting that they play a key role in the integration and maintenance of energy, oxygen, and redox homeostasis.
In addition to ubiquitination, another modification that regulates HIF-1α
protein stability is covalent ligation of the small protein SUMO, which promotes the binding of VHL to HIF-1α in a hydroxylation independent manner. 29 Ligation of SUMO to HIF-1α is reversed by the SUMO-specific protease SENP1, deficiency of
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From which results in deficient EPO production, severe anemia, and embryonic lethality of mice at midgestation. 29 Using the HIF-1α cDNA sequence to search databases, cDNA sequences encoding a related protein, now designated HIF-2α, were identified. [30] [31] [32] HIF-2α is also subject to O 2 -dependent hydroxylation, ubiquitination, and proteasomal degradation whereas under hypoxic conditions it dimerizes with HIF-1β and activates the transcription of a set of target genes, which overlaps with the target genes regulated by HIF-1α: HIF-1β heterodimers. 33 Whereas HIF-1α is expressed in all nucleated cells, the expression of HIF-2α is restricted to specific cell types, including vascular endothelial cells, renal interstitial cells, hepatocytes, cardiomyocytes, and astrocytes. 34 HIF-2α appears to plays a key role in regulating EPO production and erythropoiesis in adult mice, [35] [36] [37] although HIF-1α is also required for yolk sac erythropoiesis, 12 renal EPO production in response to acute hypoxic episodes, 38 and for the development of polycythemia in response to chronic hypoxia. 39 Whereas HIF-1α homologues are present in all metazoan species studied, it appears that HIF-2α arose coincident with the evolution of complex respiratory and circulatory systems in vertebrates.
The effect of HIF-1 and HIF-2 (i.e. HIF-1α:HIF-1β and HIF-2α:HIF-1β heterodimers, respectively) on erythropoiesis is profound and illustrates the concept that HIFs function as master regulators of oxygen homeostasis ( Figure 2 ). In addition to the control EPO production by HIF-1 and HIF-2, HIF-1 also regulates expression of the EPO receptor. 12, 40 Furthermore, HIF-1 controls the absorption and delivery of iron to the bone marrow for incorporation into the hemoglobin of red blood cells through its repression of the gene encoding hepcidin 41 and activation of
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Hereditable Disorders of Oxygen Sensing
The first hereditable disorder demonstrated to result from mutations affecting oxygen sensing is congenital Chuvash polycythemia (erythrocytosis, familial, type 2, production. 45 The R200W substitution reduces the interaction of VHL with hydroxylated HIF-1α, thereby reducing the O 2 -dependent ubiquitination and proteasomal degradation of HIF-1α. 45 As a result, the hypoxia response curve is shifted to the left, i.e. at any given O 2 concentration, HIF-1 activity will be increased in cells expressing VHL R200W compared to cells expressing wild type VHL. This is dramatically illustrated by the observation that when partial exchange transfusion is performed to lower the hematocrit in patients with Chuvash polycythemia, EPO levels begin to rise even before a normal hematocrit is attained. Not surprisingly, mice homozygous for a targeted R200W mutation of the murine Vhl gene are also polycythemic. 46 Although polycythemia is the most easily detected phenotypic manifestation of the VHL R200W/R200W genotype, recent studies indicate that oxygen sensing is globally dysregulated. 47 Individuals with Chuvash polycythemia were found to have striking abnormalities in respiratory and pulmonary vascular regulation. Basal ventilation
and heart rate responses to acute hypoxia were greatly increased compared to controls. The increased magnitude of the physiological responses to hypoxia in these patients, who have HIF-1 gain-of-function due to the hypomorphic VHL R200W alleles, mirror the decreased responses observed in Hif1a +/-mice, which have HIF-1 loss-offunction due to heterozygosity for a knockout allele at the locus encoding HIF-1α. 39, 48, 49 Other abnormalities in individuals with Chuvash polycythemia have been identified, including increased incidence of varicose veins, venous thrombosis, bleeding diatheses, vertebral hemangiomas, reduced systemic blood pressure, reduced white blood cell and platelet counts, pulmonary hypertension, cerebral vascular events, and premature mortality.
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These findings indicate that dysregulation of oxygen homeostasis has multiple, profound, systemic pathological effects.
The molecular delineation of Chuvash polycythemia demonstrated that mutation of a component of the oxygen-sensing pathway causes congenital polycythemia/erythrocytosis. The intimate relationship between oxygen sensing and erythropoiesis was further underscored when an autosomal dominant form of erythrocytosis (erythrocytosis, familial, type 3, OMIM #609820) was found to be due to a proline-to-arginine missense mutation at codon 317 (P317R) in the EGLN1 gene encoding PHD2, which renders the prolyl hydroxylase protein defective in its ability to bind and hydroxylate HIF-1α. 52 The substituted amino acid is only two residues away from aspartate-315, which binds Fe (II) directly, and close to the For personal use only. on October 3, 2017. by guest www.bloodjournal.org From catalytic site entrance in the crystal structure, suggesting that the P317R mutation may affect both Fe (II) and substrate binding. 53 Subsequently, an individual with erythrocytosis was found to be heterozygous for an arginine-to-histidine missense mutation at codon 371 (R371H) of EGLN1. 54 Residue 371 is 3 amino acids away from histidine-374, which is involved in iron binding. Thus, the R371H mutation is remarkably similar to the P317R mutation, which is also located close to an iron-binding residue, histidine-313. As expected, proline-317 and arginine-371 lie close to one another in the crystal structure of PHD2. 52 Arginine-371 is conserved in all three mammalian PHD isoforms, as well as the single PHD isoform in Drosophila melanogaster and
Caenorhabditis elegans.
Although conditional knockout of PHD2 in adult mice leads to massive and lethal erythrocytosis, heterozygosity for a complete loss-of-function allele does not result in erythrocytosis. 55 It is possible that the erythrocytosis associated with partial PHD2 deficiency develops over a prolonged period of time and was not detected or that PHD2 deficiency was complemented by compensatory increases in PHD1 or PHD3 expression. Alternatively, the mutant human PHD2 proteins described above may have dominant negative effects (i.e. the mutant protein interferes with the function of the wild type protein). The finding that the VHL missense mutation must be in the homozygous state for phenotypic manifestations also suggests the possibility that the PHD2 mutations have dominant negative effects.
Finally, in addition to the loss-of-function mutations in VHL and PHD2, a gain-of-function mutation in the EPAS1 gene encoding HIF-2α was reported as
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From another cause of familial erythrocytosis (type 4, OMIM #611783) with autosomal dominant inheritance. 56 The mutation changes glycine residue 537, which is conserved in human, mouse, chicken, frog, and zebrafish HIF-2α, to tryptophan (G537W). Glycine-537 is located carboxy terminal to proline-531, which is the hydroxylated residue in HIF-2α that is analogous to proline-564 in HIF-1α. The G537W mutation impairs the interaction of HIF-2α with PHD2 and therefore reduces hydroxylation. 56 Subsequently, additional cases of familial erythrocytosis were found to be due to G537R, M535V, and M535I missense mutations at the EPAS1 locus. 57, 58 Unlike the mutations in VHL and PHD2 that are described above, there is no evidence that the mutations in EPAS1 affect HIF-1α protein levels and this finding therefore complements loss-of-function data from mice described above indicating that HIF-2α plays a critical role in regulating erythropoiesis. Thus far, no studies have reported whether patients with familial erythrocytosis due to missense mutations affecting PHD2 or HIF-2α manifest additional evidence of dysregulated oxygen homeostasis as described above for individuals with Chuvash polycythemia.
Thus, 15 years after analysis of EPO gene regulatory elements led to the discovery of HIF-1, 6 which led in turn to the discovery of VHL 19 and the PHDs, 16, 17 mutations in genes encoding all three of these essential components of the oxygen sensing system have been identified in humans with familial erythrocytosis ( Figure   3 ). Gain-of-function mutations in the EPO receptor also cause familial erythrocytosis (type 1, OMIM #133100). 59 It is likely that additional patients with mutations in loci encoding other components of the O 2 sensing pathway remain to be identified.
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Pharmacological Inhibition of Hydroxylases
The identification of chemical compounds that can inhibit the PHDs, such as the α-ketoglutarate (2-oxoglutarate) analogue dimethyloxalylglycine, 16, 60 provides a potential novel oral therapy for stimulating erythropoiesis in patients with chronic kidney disease, which is currently achieved by subcutaneous injection of recombinant human EPO. Clinical trials of prolyl hydroxylase inhibitors are underway (e.g. NCT00456053, www.clinicaltrials.gov). However, it is not clear whether it will be possible to selectively stimulate erythropoiesis on a chronic basis without undesired side effects associated with PHD inhibition, such as the pathological findings associated with Chuvash polycythemia described above, as well as additional side effects that may occur due to the inhibition of other iron-and oxoglutarate-dependent dioxygenases. 
